Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilon Health (AGLResearch Report) and BioMarin Pharmaceutical (BMRNResearch Report) with bullish sentiments.

Agilon Health (AGL)

Jefferies analyst Brian Tanquilut maintained a Buy rating on Agilon Health yesterday and set a price target of $35.00. The company’s shares closed last Thursday at $19.23, close to its 52-week low of $14.36.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 6.1% and a 54.7% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Privia Health Group, and AmerisourceBergen.

Currently, the analyst consensus on Agilon Health is a Strong Buy with an average price target of $31.67.

See Insiders’ Hot Stocks on TipRanks >>

BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company’s shares closed last Thursday at $75.43.

According to TipRanks.com, Tewari is a 4-star analyst with an average return of 29.9% and a 57.5% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Madrigal Pharmaceuticals, and Cytokinetics.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.31, a 45.8% upside from current levels. In a report issued on February 24, Truist Financial also reiterated a Buy rating on the stock with a $135.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AGL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed